
CareDx (CDNA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
84.7M
Gross Profit
56.3M
66.45%
Operating Income
-8.0M
-9.46%
Net Income
-10.4M
-12.23%
EPS (Diluted)
$-0.19
Balance Sheet Metrics
Total Assets
489.6M
Total Liabilities
110.3M
Shareholders Equity
379.3M
Debt to Equity
0.29
Cash Flow Metrics
Operating Cash Flow
-6.9M
Free Cash Flow
-28.2M
Revenue & Profitability Trend
CareDx Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 333.8M | 280.3M | 321.8M | 296.4M | 192.2M |
Cost of Goods Sold | 109.6M | 102.0M | 112.2M | 97.4M | 63.1M |
Gross Profit | 224.2M | 178.3M | 209.6M | 199.0M | 129.1M |
Gross Margin % | 67.2% | 63.6% | 65.1% | 67.1% | 67.2% |
Operating Expenses | |||||
Research & Development | 72.4M | 81.9M | 90.4M | 76.5M | 48.9M |
Selling, General & Administrative | 205.5M | 201.2M | 196.4M | 152.2M | 102.7M |
Other Operating Expenses | - | - | - | - | -4.8M |
Total Operating Expenses | 277.9M | 283.1M | 286.8M | 228.7M | 146.8M |
Operating Income | -53.8M | -104.7M | -77.2M | -29.7M | -17.7M |
Operating Margin % | -16.1% | -37.4% | -24.0% | -10.0% | -9.2% |
Non-Operating Items | |||||
Interest Income | 11.8M | 11.9M | 3.8M | 160.0K | 271.0K |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | 94.8M | -97.3M | -2.8M | -2.5M | -2.3M |
Pre-tax Income | 52.9M | -190.1M | -76.2M | -32.1M | -19.8M |
Income Tax | 310.0K | 141.0K | 379.0K | -1.4M | -1.0M |
Effective Tax Rate % | 0.6% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | 52.5M | -190.3M | -76.6M | -30.7M | -18.7M |
Net Margin % | 15.7% | -67.9% | -23.8% | -10.3% | -9.7% |
Key Metrics | |||||
EBITDA | -128.5M | 13.7M | -61.3M | -17.9M | -6.7M |
EPS (Basic) | $1.00 | $-3.54 | $-1.44 | $-0.59 | $-0.40 |
EPS (Diluted) | $0.93 | $-3.54 | $-1.44 | $-0.59 | $-0.40 |
Basic Shares Outstanding | 52773247 | 53764705 | 53321625 | 52241076 | 46481772 |
Diluted Shares Outstanding | 52773247 | 53764705 | 53321625 | 52241076 | 46481772 |
Income Statement Trend
CareDx Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 114.7M | 82.2M | 89.9M | 348.5M | 134.7M |
Short-term Investments | 146.0M | 153.2M | 203.2M | 0 | 90.0M |
Accounts Receivable | 64.6M | 51.1M | 66.3M | 59.8M | 34.6M |
Inventory | 19.5M | 19.5M | 19.2M | 17.2M | 10.0M |
Other Current Assets | 7.1M | 7.8M | 9.2M | 7.9M | 3.8M |
Total Current Assets | 351.8M | 313.7M | 387.8M | 433.4M | 273.1M |
Non-Current Assets | |||||
Property, Plant & Equipment | 24.3M | 29.9M | 34.7M | 18.0M | 15.2M |
Goodwill | 118.9M | 126.4M | 118.1M | 124.2M | 92.1M |
Intangible Assets | 38.2M | 45.7M | 43.1M | 50.2M | 44.4M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 2.8M | 1.9M | 4.4M | 6.0M | 1.3M |
Total Non-Current Assets | 139.2M | 153.1M | 155.1M | 133.3M | 95.4M |
Total Assets | 491.0M | 466.8M | 543.0M | 566.6M | 368.5M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 7.7M | 12.9M | 9.9M | 13.3M | 9.7M |
Short-term Debt | 6.1M | 5.9M | 5.6M | 4.0M | 2.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 2.5M | 5.6M | 2.3M | 4.7M | 738.0K |
Total Current Liabilities | 89.4M | 78.1M | 76.0M | 77.3M | 69.2M |
Non-Current Liabilities | |||||
Long-term Debt | 22.3M | 28.3M | 33.4M | 17.4M | 16.1M |
Deferred Tax Liabilities | 164.0K | 136.0K | 0 | 415.0K | 1.3M |
Other Non-Current Liabilities | 819.0K | 96.6M | 249.0K | 455.0K | 240.0K |
Total Non-Current Liabilities | 23.2M | 127.4M | 36.1M | 23.4M | 21.6M |
Total Liabilities | 112.6M | 205.5M | 112.1M | 100.7M | 90.8M |
Equity | |||||
Common Stock | 51.0K | 49.0K | 52.0K | 52.0K | 49.0K |
Retained Earnings | -626.2M | -678.3M | -460.4M | -383.2M | -352.5M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 378.4M | 261.3M | 430.9M | 465.9M | 277.7M |
Key Metrics | |||||
Total Debt | 28.4M | 34.2M | 39.0M | 21.4M | 18.1M |
Working Capital | 262.5M | 235.6M | 311.9M | 356.1M | 203.9M |
Balance Sheet Composition
CareDx Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 52.5M | -190.3M | -76.6M | -30.7M | -18.7M |
Depreciation & Amortization | 19.8M | 19.8M | 16.0M | 11.9M | 9.5M |
Stock-Based Compensation | 66.4M | 49.1M | 46.6M | 36.1M | 23.4M |
Working Capital Changes | -25.9M | 14.1M | -15.2M | -54.0M | 8.8M |
Operating Cash Flow | 113.7M | -111.6M | -28.2M | -36.4M | 23.3M |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | 0 | -6.7M | -610.0K | -15.4M | 0 |
Investment Purchases | -160.9M | -202.1M | -315.1M | -5.5M | -90.0M |
Investment Sales | 166.9M | 258.5M | 111.6M | 88.9M | 0 |
Investing Cash Flow | 6.0M | 49.7M | -204.2M | 68.0M | -90.0M |
Financing Activities | |||||
Share Repurchases | -522.0K | -27.5M | -642.0K | 0 | 0 |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | 0 |
Debt Repayment | - | 0 | 0 | -66.0K | -183.0K |
Financing Cash Flow | -15.9M | -31.2M | -9.2M | 170.7M | 153.4M |
Free Cash Flow | 31.6M | -27.6M | -49.6M | -39.6M | 23.1M |
Net Change in Cash | 103.8M | -93.2M | -241.5M | 202.3M | 86.7M |
Cash Flow Trend
CareDx Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
11.91
Forward P/E
21.57
Price to Book
2.03
Price to Sales
1.95
PEG Ratio
0.03
Profitability Ratios
Profit Margin
17.06%
Operating Margin
-12.43%
Return on Equity
19.64%
Return on Assets
-5.85%
Financial Health
Current Ratio
3.30
Debt to Equity
8.90
Beta
2.22
Per Share Data
EPS (TTM)
$1.05
Book Value per Share
$6.15
Revenue per Share
$6.29
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
cdna | 665.9M | 11.91 | 2.03 | 19.64% | 17.06% | 8.90 |
Thermo Fisher | 184.1B | 28.17 | 3.64 | 13.42% | 15.24% | 69.62 |
Danaher | 146.0B | 43.29 | 2.79 | 6.68% | 14.21% | 35.45 |
Twist Bioscience | 1.7B | -7.35 | 3.53 | -17.58% | -23.52% | 19.48 |
Neogen | 1.2B | 865.00 | 0.59 | -41.88% | -122.06% | 44.14 |
Grail | 1.1B | -0.49 | 0.49 | -17.68% | -62.12% | 2.69 |
Financial data is updated regularly. All figures are in the company's reporting currency.